Trials in Progress Submission Guidelines

SNMMI recognizes the importance of bringing together researchers to discuss ongoing trials. Trials in Progress posters provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. In addition, Trials in Progress highlight the transition of emerging biologic pathways and new agents into the clinic—providing "coming attractions" for oncologists in clinical practice.

All phases of clinical research (phases I to III, supportive care, nonpharmacologic interventions) may be considered for inclusion as a Trials in Progress submission. Trials submitted to this session are ongoing and have not reached pre-specified endpoints for analysis. As such, inclusion of results would be improper and is strictly forbidden.

Specific Guidelines

- The nonrefundable $40 (USD) submission fee will apply.
- All conflict of interest policies apply.
- Abstracts should be organized according to two sections, Backgrounds and Methods, as described below:
  - **Background**
    - Scientific background/rationale for the trial
    - Preclinical and/or earlier-phase clinical data that have already been publicly presented or published may be included with references. The Trials in Progress abstract should not be used to present preclinical or earlier-phase clinical data for the first time
    - Correlative studies of particular interest
  - **Methods**
    - Trial design and statistical methods, highlighting any novel aspects of the design
    - Treatment or intervention planned
    - Major eligibility criteria, highlighting unusual aspects
    - Current enrollment without providing results or endpoints
      - Phase I studies may say, "Cohorts 1 and 2 have been completed without DLT. Enrollment to cohort 3 began in January 2016"
      - Phase II studies may report, "8 of planned 32 patients have been enrolled" or "Prespecified activity goal for the first stage of accrual was met; second stage accrual began in January 2019"
      - Phase III trials may report, "The DMC last reviewed the trial in December 2019 and suggested that the trial continue as planned"
    - **Enrollment must have already begun or have been completed with no data analysis available by the submission deadline (there are no exceptions to this criterion).** It is acceptable if the trial has not enrolled its first patient yet.
- **Clinical trial registry number (required)**
- The following information is not acceptable in a Trials in Progress abstract and/or poster:
  - Any preliminary data including toxicity, response rate, pharmacokinetic, or correlative analyses. Abstracts including results or preliminary data will be rejected without further review.
  - Proprietary drug names or the names of drug manufacturers in the title or body of the abstract. If necessary, you may include the proprietary drug name in parentheses directly after the generic name on first use in the body of the abstract. SNMMI reserves the right to replace proprietary names with generic names to adhere to this requirement.
  - Information about pricing, fees, or reimbursement related to trial participation.